Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB011 in advanced solid tumors
NCT04400383Phase 1Completed
- Sponsor
- CARsgen Therapeutics
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ab011 in solid tumor, gastric cancer (GC), pancreatic adenocarcinoma (PDAC) and 1 more (3 arms), sponsored by CARsgen Therapeutics. Primary endpoints: Incidence of adverse events at 6 months, Incidence of serious adverse events at 6 months and 1 more. Started Jun 2020; status: completed.
02
Drugs
ab011
03
Conditions
solid tumorgastric cancer (GC)pancreatic adenocarcinoma (PDAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04400383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400383.